GL1X · GenesisL1 explorer

MolNFT v1 · #123621 · protein

Crystal structure of ebola glycoprotein

5JQ3 · Envelope glycoprotein 1,ENVELOPE glycoprotein 1,ENVELOPE…: “Crystal structure of ebola glycoprotein”. X-ray diffraction, 3 ligands (NAG, MAN, BMA), 8 pockets (best druggability 0.60). MolNFT v1 #123621 on GenesisL1: 3D structure…

PDB
5JQ3
Type
protein
Length
393 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Envelope glycoprotein 1,ENVELOPE glycoprotein 1,ENVELOPE glycoprotein 1; Envelope…
UniProt
Q05320
Ligands
NAG, MAN, BMA
Pockets
8 · best druggability 0.60

Structure

x-ray diffraction · 2 distinct chains · 20% helix, 30% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AEnvelope glycoprotein 1,ENVELOPE glycoprotein 1,ENVELOPE glycoprotein 1protein26310% helix, 39% strandQ05320
BEnvelope glycoprotein 2protein13041% helix, 12% strandQ05320

Ligands and binding sites

  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · 7 copies · chains A, B
  • MAN · alpha-D-mannopyranose · sugar · 2 copies · chains A
  • BMA · beta-D-mannopyranose · sugar
  • GOL · Glycerol · additive · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

8 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11570.600.8327empty
22170.590.8030empty
31030.390.7616empty
4620.390.8013empty
51080.390.7519GOL

Interfaces

1 interface between chains.

  • A–B · 2866 Ų buried · 31 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 6 glycan, 5 disulfide (N-glycosylation, disulfide).

Compared structures

  • 5JQ3 · Crystal structure of Ebola glycoprotein · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.